There are currently 91 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Autism participants are Ohio, Illinois, California and New York.
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
NCT05495464
Recruiting
To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma, Mantle Cell Lymphoma
Register for Updates
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
NCT00582621
Recruiting
The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease a... Read More
Gender:
All
Ages:
All
Trial Updated:
01/19/2024
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +5 locations
Conditions: Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, Renal Cancer
Register for Updates
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
NCT05929612
Recruiting
To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses after that.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
NCT02106988
Recruiting
The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
NCT05921253
Recruiting
This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.
Gender:
All
Ages:
Between 50 years and 99 years
Trial Updated:
12/21/2023
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Breast Cancer, Lymphoma
Register for Updates
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
NCT02323867
Recruiting
This is a single arm pilot study for patients using α/β T cell-depleted peripheral Stem Cell Transplantation (PSCT) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and graft versus host disease (GVHD), and one year leukemia free survival.
Gender:
All
Ages:
23 years and below
Trial Updated:
12/19/2023
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Leukemia, Lymphoma, Myelodysplasia
Register for Updates
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
NCT05464719
Recruiting
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/13/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Large B-cell Lymphoma, Lymphoma
Register for Updates
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
NCT05540340
Recruiting
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height and weight. The population PK model, tested in this study, uses information based on people who have previously received melphalan and aims to calculate an optimal dose separately for each person. Study researchers think that the dose calculated using... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
12/07/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Register for Updates
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
NCT05294367
Recruiting
This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium and it typically comes from the food we eat. In patients who are ill, magnesium is often replaced intravenously (IV) through a vein or by mouth. This study may help researchers find out if being on a magnesium rich diet and using a magnesium lotion on... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Lymphoma
Register for Updates
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
NCT03823534
Recruiting
Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to NSAID use. Orthopedic oncology, however, has a unique subset of patients that undergo prophylactic placement of intramedullary femoral nails. Because no fracture is present, these patients do not rely on inflammatory healing factors, allowing for post... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Saint Louis University, Saint Louis, Missouri
Conditions: Bone Metastases, Lymphoma, Multiple Myeloma, Opioid Use, Pain
Register for Updates
A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
NCT01697930
Recruiting
This is a Phase I study. This study is the first time that a new experimental drug called 18FFluoroglutamine, or F-Glutamine, is being used in people. F-Glutamine is a drug designed to be used with PET scanners that can 'see' where F-Glutamine goes in the body, after its injected. PET scanners are one of the kinds of scanners you normally find in a hospital radiology department. The researchers have found that tumors in animals absorb F-Glutamine. The researchers believe that scans with F-Glutam... Read More
Gender:
All
Ages:
Between 21 years and 90 years
Trial Updated:
11/28/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Solid Malignancy, Lymphoma
Register for Updates
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
NCT05683171
Recruiting
To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates